Saturday, 24 Oct 2026

Empowering Chinese Pharma’s Global Expansion

Contact US
Insight,  China's Pharmaceutical Industry
  • Home
  • About US
  • Policy Hub
  • Categories
    • Drug
    • Company
    • Deals
    • Policy / Regulatory
    • Medical Device
    • R&D
    • Legal / IP
    • Digital
  • Privacy Policy
  • Contact US
My News
  • Cancer
  • Clinical trial approval / initiation
  • Product approvals
  • Clinical trial results
  • Finance
  • ADC / XDC
  • Finanical Reports
  • Biotech
  • Market approval filings
  • PD-1/L1
Insight,  China's Pharmaceutical IndustryInsight,  China's Pharmaceutical Industry
  • Read History
Search
  • Pages
    • Home
    • Blog Index
    • POLICY HUB
    • Contact Us
  • Personalized
    • Read History
  • Categories
    • Company
    • Drug
    • Policy / Regulatory
    • Medical Device
    • R&D
    • Digital
    • Legal / IP
    • Deals
Have an existing account? Sign In
Follow US
Immunochina Pharmaceuticals' IM19 CAR-T Therapy Accepted for Review by NMPA
CompanyDrug

Immunochina Pharmaceuticals’ IM19 CAR-T Therapy Accepted for Review by NMPA

November 28, 2024
Thederma’s TAP-1503 Cream Approved by China’s NMPA for Atopic Dermatitis Treatment
CompanyDrug

Thederma’s TAP-1503 Cream Approved by China’s NMPA for Atopic Dermatitis Treatment

November 28, 2024
Novartis's Kisqali Approved by EC for Adjuvant Treatment of High-Risk Early Breast Cancer
CompanyDrug

Novartis’s Kisqali Approved by EC for Adjuvant Treatment of High-Risk Early Breast Cancer

November 28, 2024
Sanofi Launches Modulus, a Pioneering Manufacturing Facility in Singapore
Company

Sanofi Launches Modulus, a Pioneering Manufacturing Facility in Singapore

November 28, 2024
Chia Tai Tianqing's Benmelstobart Combo Approved by NMPA for Endometrial Cancer Treatment
CompanyDrug

Chia Tai Tianqing’s Benmelstobart Combo Approved by NMPA for Endometrial Cancer Treatment

December 9, 2024
Sichuan Kelun-Biotech's SKB264/MK-2870 Approved by NMPA for Triple Negative Breast Cancer
CompanyDrug

Sichuan Kelun-Biotech’s SKB264/MK-2870 Approved by NMPA for Triple Negative Breast Cancer

November 27, 2024
NHC Aims for Nationwide Inspection Result Sharing in Medical Consortia by 2030
Policy / Regulatory

NHC Aims for Nationwide Inspection Result Sharing in Medical Consortia by 2030

November 27, 2024
Ji Xing Pharmaceuticals' Varenicline Nasal Spray Gains NMPA Approval for Xerophthalmia
CompanyDrug

CORXEL’s Varenicline Nasal Spray Approved by NMPA for Dry Eye Treatment

November 29, 2024
Arrowhead and Sarepta Seal $11.38 Billion Global Licensing Deal for Rare Disease Treatments
CompanyDeals

Arrowhead and Sarepta Seal $11.38 Billion Global Licensing Deal for Rare Disease Treatments

November 27, 2024
Pfizer Partners with CR Pharma to Expand Cancer Drug Access in China
CompanyDrug

Pfizer Partners with CR Pharma to Expand Cancer Drug Access in China

November 27, 2024
Roche’s Evrysdi Receives Patent Term Extension in China, Extending Protection to 2035
Legal / IP

Roche’s Evrysdi Receives Patent Term Extension in China, Extending Protection to 2035

November 27, 2024
CanSino Biologics' Menhycia Vaccine Aims to Expand Age Range with NMPA Filing
CompanyDrug

CanSino Biologics’ Menhycia Vaccine Aims to Expand Age Range with NMPA Filing

December 23, 2024
1 2 3 4 5 6 … 31 32
Insight,  China's Pharmaceutical Industry

Information You Can Trust: Stay instantly connected with breaking stories and live updates. From politics and technology to entertainment and beyond, we provide real-time coverage you can rely on, making us your dependable source for 24/7 news.

Youtube Medium Rss

About Company

  • Contact Us
  • Advertise with US
  • Complaint
  • Our Team
  • Our Values
  • Privacy Policy
Subscribe Now for Real-time Updates on the Latest Stories!

© 2026 Fineline Information & Technology. Independent intelligence on China’s pharmaceutical industry.  All Rights Reserved.

Fineline Information & Technology
Welcome to Fineline Cube!
Username or Email Address
Password

Lost your password?

Not a member? Sign Up